Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization.

Détails

Ressource 1Télécharger: BIB_823C6E755633.P001.pdf (980.18 [Ko])
Etat: Serval
Version: de l'auteur
ID Serval
serval:BIB_823C6E755633
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization.
Périodique
Journal of Cellular and Molecular Medicine
Auteur(s)
Weiss A., van Beijnum J.R., Bonvin D., Jichlinski P., Dyson P.J., Griffioen A.W., Nowak-Sliwinska P.
ISSN
1582-4934 (Electronic)
ISSN-L
1582-1838
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
18
Numéro
3
Pages
480-491
Langue
anglais
Notes
Publication types: Journal Article PDF: Original Article
Résumé
Photodynamic therapy (PDT) is an effective clinical treatment for a number of different cancers. PDT can induce hypoxia and inflammation, pro-angiogenic side effects, which may counteract its angio-occlusive mechanism. The combination of PDT with anti-angiogenic drugs offers a possibility for improved anti-tumour outcome. We used two tumour models to test the effects of the clinically approved angiostatic tyrosine kinase inhibitors sunitinib, sorafenib and axitinib in combination with PDT, and compared these results with the effects of bevacizumab, the anti-VEGF antibody, for the improvement of PDT. Best results were obtained from the combination of PDT and low-dose axitinib or sorafenib. Molecular analysis by PCR revealed that PDT in combination with axitinib suppressed VEGFR-2 expression in tumour vasculature. Treatment with bevacizumab, although effective as monotherapy, did not improve PDT outcome. In order to test for tumour vessel normalization effects, axitinib was also applied prior to PDT. The absence of improved PDT outcome in these experiments, as well as the lack of increased oxygenation in axitinib-treated tumours, suggests that vascular normalization did not occur. The current data imply that there is a future for certain anti-angiogenic agents to further improve the efficacy of photodynamic anti-cancer therapy.
Pubmed
Web of science
Création de la notice
06/04/2014 16:39
Dernière modification de la notice
03/03/2018 18:49
Données d'usage